RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Anil Shanker to Neoplasms

This is a "connection" page, showing publications Anil Shanker has written about Neoplasms.
Connection Strength

2.826
  1. Renrick AN, Dunbar ZT, Shanker A. Update?on the current revolution in cancer immunotherapy. Immunotherapy. 2019 01; 11(1):15-20.
    View in: PubMed
    Score: 0.342
  2. Shanker A, Thounaojam MC, Mishra MK, Dikov MM. Innate-Adaptive Immune Crosstalk 2016. J Immunol Res. 2017; 2017:3503207.
    View in: PubMed
    Score: 0.303
  3. Pulliam SR, Uzhachenko RV, Adunyah SE, Shanker A. Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunol Lett. 2016 Jan; 169:61-72.
    View in: PubMed
    Score: 0.275
  4. Shanker A, Thounaojam MC, Mishra MK, Dikov MM, Uzhachenko RV. Innate-Adaptive Immune Crosstalk. J Immunol Res. 2015; 2015:982465.
    View in: PubMed
    Score: 0.274
  5. Pellom ST, Dudimah DF, Thounaojam MC, Sayers TJ, Shanker A. Modulatory effects of bortezomib on host immune cell functions. Immunotherapy. 2015; 7(9):1011-22.
    View in: PubMed
    Score: 0.271
  6. de Aquino MT, Malhotra A, Mishra MK, Shanker A. Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett. 2015 Aug; 166(2):117-33.
    View in: PubMed
    Score: 0.267
  7. Malhotra A, Shanker A. NK cells: immune cross-talk and therapeutic implications. Immunotherapy. 2011 Oct; 3(10):1143-66.
    View in: PubMed
    Score: 0.207
  8. Shanker A, Marincola FM. Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunol Immunother. 2011 Aug; 60(8):1061-74.
    View in: PubMed
    Score: 0.202
  9. Shanker A, Brooks AD, Jacobsen KM, Wine JW, Wiltrout RH, Yagita H, Sayers TJ. Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity. Cancer Res. 2009 Aug 15; 69(16):6615-23.
    View in: PubMed
    Score: 0.178
  10. Shanker A, Sayers T. Sensitizing tumor cells to immune-mediated cytotoxicity. Adv Exp Med Biol. 2007; 601:163-71.
    View in: PubMed
    Score: 0.149
  11. Goruganthu MUL, Shanker A, Dikov MM, Carbone DP. Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings. Front Immunol. 2020; 11:1958.
    View in: PubMed
    Score: 0.096
  12. Uzhachenko RV, Shanker A. CD8+ T Lymphocyte and NK Cell Network: Circuitry in the Cytotoxic Domain of Immunity. Front Immunol. 2019; 10:1906.
    View in: PubMed
    Score: 0.089
  13. Uzhachenko R, Shanker A, Yarbrough WG, Ivanova AV. Mitochondria, calcium, and tumor suppressor Fus1: At the crossroad of cancer, inflammation, and autoimmunity. Oncotarget. 2015 Aug 28; 6(25):20754-72.
    View in: PubMed
    Score: 0.068
  14. Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, Sayers TJ, Hudig D, Murphy WJ. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol. 2008 Jan 01; 180(1):163-70.
    View in: PubMed
    Score: 0.040
  15. Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol. 2006 Feb; 84(1):87-98.
    View in: PubMed
    Score: 0.035
  16. Shanker A. Is thymus redundant after adulthood? Immunol Lett. 2004 Feb 15; 91(2-3):79-86.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support